This Article Full Text Full Text (PDF) All Versions of this Article: 34/6/1507    most recent 01.STR.0000071760.66720.5Fv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ellsworth, J. L. Articles by Kindy, M. S. Search for Related Content PubMed PubMed Citation Articles by Ellsworth, J. L. Articles by Kindy, M. S. Related Collections Animal models of human disease Growth factors/cytokines Neuroprotectors

(Stroke. 2003;34:1507.)
© 2003 American Heart Association, Inc.

Original Contributions

Fibroblast Growth Factor-18 Reduced Infarct Volumes and Behavioral Deficits After Transient Occlusion of the Middle Cerebral Artery in Rats

Jeff L. Ellsworth, PhD; Richard Garcia, BS; Jin Yu, MD Mark S. Kindy, PhD

From ZymoGenetics, Inc, Seattle, Wash (J.L.E., R.G.); Department of Physiology and Neuroscience, Stroke Program and Center on Aging, Medical University of South Carolina, and Ralph H. Johnson, Veterans Affairs Medical Center, Charleston (J.Y., M.S.K.); and Molecular Therapeutics, Inc, Mt Pleasant, SC (M.S.K.).

Correspondence to Jeff L. Ellsworth, PhD, ZymoGenetics, Inc, 1201 Eastlake Ave E, Seattle, WA 98102. E-mail jefe{at}zgi.com

Background and Purpose— Fibroblast growth factor 18 (FGF18) is expressed in rodent brain and is a trophic factor for neuron-derived cells in culture. The purpose of the present study was to evaluate whether FGF18 was neuroprotective in a rat model of cerebral ischemia and to compare the results with those obtained with FGF2.

Methods— Cerebral ischemia was produced in rats by a transient 2-hour occlusion of the middle cerebral artery (MCAo) with an intraluminal filament followed by 22-hour reperfusion. Starting 15 minutes after MCAo, FGF18 or FGF2 was administered by a 3-hour intravenous infusion. Infarct volumes and behavioral deficits were measured 24 hours after MCAo.

Results— Infusion of FGF18 produced dose-dependent reductions in infarct volumes and improvements in tests of reference and working memory, motor ability, and exploratory behavior. FGF18 was more efficacious than FGF2 on virtually all measures examined. The reductions in infarct volume and behavioral deficit were associated with FGF-mediated increases in regional cerebral blood flow.

Conclusions— These results demonstrate that FGF18 is an effective neuroprotective agent in a rat model of transient MCAo.

Key Words: animal models • growth factors • neuroprotection • rats

This article has been cited by other articles:

				A. F. Terwisscha van Scheltinga, S. C. Bakker, and R. S. Kahn Fibroblast Growth Factors in Schizophrenia Schizophr Bull, May 8, 2009; (2009) sbp033v1. [Abstract] [Full Text] [PDF]

				NINDS ICH Workshop Participants Priorities for Clinical Research in Intracerebral Hemorrhage: Report From a National Institute of Neurological Disorders and Stroke Workshop Stroke, March 1, 2005; 36(3): e23 - e41. [Abstract] [Full Text] [PDF]